Medical Condition News

RSS

Nanotechnology-based biosensor may allow early cancer, pathogen detection

A nanotechnology-based biosensor being developed by Kansas State University researchers may allow early detection of both cancer cells and pathogens, leading to increased food safety and reduced health risks.

30 Mar 2011

California's aging LGB more likely to suffer from certain chronic conditions

Members of California's aging lesbian, gay and bisexual population are more likely to suffer from certain chronic conditions, even as they wrestle with the challenges of living alone in far higher numbers than the heterosexual population, according to new policy brief from the UCLA Center for Health Policy Research.

30 Mar 2011

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

Silence Therapeutics plc a leading global RNA interference therapeutics company, announces that interim data from its ongoing Phase I clinical study of Atu027, the Company's lead internal therapeutic candidate, have been accepted for poster presentation at the 2011 American Society of Clinical Oncology Annual Meeting.

30 Mar 2011

CancerForward announces new national outreach and partnering program

CancerForward: The Foundation for Cancer Survivors today announced the creation of ConnectToForward, a fundamental initiative of the Foundation's three-prong mission to connect, educate and share information among cancer survivors through its website, cancerforward.org.

30 Mar 2011

New study: Periodontal therapy can help reduce medical costs for patients with diabetes

The results from a new CIGNA study support that there is a potential association between treated periodontal disease and reduced medical costs for patients with diabetes.

30 Mar 2011

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency for the approval of Erbitux in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer with high epidermal growth factor receptor expression.

30 Mar 2011

Pathfinder cell-based therapy reverses diabetes in mouse model

Pathfinder, LLC, a private biotechnology company focused on the treatment of diseases characterized by organ-specific cell damage, today announced publication of promising preclinical data demonstrating that the Company's unique cell-based therapy is able to completely reverse diabetes in a mouse model.

30 Mar 2011

ADI, Fondation Médéric Alzheimer honor Britain's psychiatry professor with international award

Dr. Sube Banerjee, one of the world's leading experts on Alzheimer's disease is the recipient of an international award for the best evidence-based psychosocial intervention for people with dementia and their caregivers.

30 Mar 2011

Vexim granted FDA approval for COHESION bone cement

Vexim specialises in medical instruments and the minimally invasive treatment of vertebral fractures. The company recently announced that it had been awarded FDA certification for its flagship product COHESION™, a bone cement for injection into the vertebra for its fixation following minimally invasive spine repair with the company's SpineJack® device, or following conventional vertebroplasty.

30 Mar 2011

Valeant receives European Commission marketing authorization for Trobalt

Meda's partner for retigabine, Valeant Pharmaceuticals International, Inc., today announced that the European Commission has granted the marketing authorization for Trobalt™ (retigabine) in the epilepsy therapy area.

30 Mar 2011

Navy sonar experts develop new medical device for stroke detection

A medical device developed by retired U.S. Navy sonar experts, using submarine technology, is a new paradigm for the detection, diagnosis and monitoring of stroke, says a team of interventional radiologists at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

Attacks by specific type of immune cells cause inflammations of heart muscle

Scientists of the German Cancer Research Center, jointly with colleagues in the United States, have found out that inflammations of the heart muscle are caused by attacks of a specific type of immune cells. These immune cells attack the body's own tissue because during their maturation they did not have the chance to develop tolerance against a protein that is only found in the heart muscle.

30 Mar 2011

Stanford pediatrics receives Genzyme/ACMG award for biochemical genetic research

Anna-Kaisa Niemi, MD, Ph.D., a resident in Medical Genetics in the Department of Pediatrics, Division of Medical Genetics at the Stanford University Medical Center, in Stanford Calif., was honored as the 2011-2012 recipient of the Genzyme/American College of Medical Genetics Foundation Clinical Genetics Fellowship in Biochemical Genetics at the ACMG 2011 Annual Clinical Genetics Meeting in Vancouver, BC, Canada.

30 Mar 2011

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Oral antiplatelet therapy Effient has been added to the updated clinical practice guidelines as a Class I recommended treatment option for patients undergoing percutaneous coronary intervention fter experiencing heart-related chest pain at rest or non-ST segment elevation myocardial infarction.

30 Mar 2011

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

According to a comprehensive global survey of orthopedic surgeons conducted by iData Research, the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.

30 Mar 2011

Prostate Oncology Specialists introduces new blog for patients

Prostate Oncology Specialists, Inc. announces the launch of the "Prostate Snatchers" blog. It features contributions from a medical oncologist, Mark Scholz MD, who specializes only in prostate cancer and a prostate cancer patient, Ralph H. Blum.

30 Mar 2011

Study examines plant-soil relationship and uptake of contaminants in ryegrass

The environmental concern is great when considering the role of toxic contaminants in the plant-soil relationship. Understanding plant's absorption and accumulation of these contaminants from the soil would be incredibly beneficial.

30 Mar 2011

Patients with dystonia can benefit from deep brain stimulation therapy

Patients suffering from dystonia, an uncommon yet potentially crippling movement disorder, get better results if they begin deep brain stimulation therapy sooner rather than later, according to an international study published in the March issue of the Journal of Neurology.

30 Mar 2011

Porter Adventist Hospital inaugurates new clinic to treat TIA

A transient ischemic attack is a form of minor stroke that can last just minutes, often without any lingering symptoms. But if left untreated, those who have one are at an estimated 25 percent greater risk of having another stroke or other complication within 90 days.

30 Mar 2011

Eya1 phosphatase controls fate of embryonic lung epithelial stem cells

Investigators at The Saban Research Institute of Children's Hospital Los Angeles have provided the first evidence that Eya1 protein phosphatase is a crucial regulator of the development of embryonic lung epithelial stem cells.

30 Mar 2011

Medical Condition News

Nanotechnology-based biosensor may allow early cancer, pathogen detection

California's aging LGB more likely to suffer from certain chronic conditions

SLN to present Atu027 Phase I study data against solid cancer at ASCO Annual Meeting

CancerForward announces new national outreach and partnering program

New study: Periodontal therapy can help reduce medical costs for patients with diabetes

Merck submits Erbitux indication extension to EMA for NSCLC treatment

Pathfinder cell-based therapy reverses diabetes in mouse model

ADI, Fondation Médéric Alzheimer honor Britain's psychiatry professor with international award

Vexim granted FDA approval for COHESION bone cement

Valeant receives European Commission marketing authorization for Trobalt

Navy sonar experts develop new medical device for stroke detection

Attacks by specific type of immune cells cause inflammations of heart muscle

Stanford pediatrics receives Genzyme/ACMG award for biochemical genetic research

ACCF, AHA guidelines recognize Effient as Class I treatment option for patients with ACS-PCI

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

Prostate Oncology Specialists introduces new blog for patients

Study examines plant-soil relationship and uptake of contaminants in ryegrass

Patients with dystonia can benefit from deep brain stimulation therapy

Porter Adventist Hospital inaugurates new clinic to treat TIA

Eya1 phosphatase controls fate of embryonic lung epithelial stem cells

The CAR T Veteran: A Journey of Resilience, Remission, and Advocacy

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Latest News